ArticlePain2022
Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization.
Article in Pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Molecular Mechanisms and Therapeutic Targets for Pain Following Osteoporotic Vertebral Fractures.Journal of pain research · 2026Review
- Osteoimmunology of Osteoporosis in Rheumatoid Arthritis: Emerging Mechanisms and Therapeutic Implications.International journal of general medicine · 2025Review
- Role of TLR4 activation and signaling in bone remodeling, and afferent sprouting in serum transfer arthritis.Arthritis research & therapy · 2024Article
- An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis.Nature reviews. Rheumatology · 2024Review
- The peculiar features, diversity and impact of citrulline-reactive autoantibodies.Nature reviews. Rheumatology · 2024Review
- Sensory ASIC3 channel exacerbates psoriatic inflammation via a neurogenic pathway in female mice.Nature communications · 2024Article
- Immune drivers of physiological and pathological pain.The Journal of experimental medicine · 2024Article
- Neutrophils in Inflammatory Bone Diseases.Current osteoporosis reports · 2024Review
- Exploratory metabolomic analysis for characterizing the metabolic profile of the urinary bladder under estrogen deprivation.Frontiers in endocrinology · 2024Article
- Chronic Pain and Bone-Related Pathologies: A Narrative Review.Journal of pain research · 2024Review
- A Rare Skeletal Disorder, Fibrous Dysplasia: A Review of Its Pathogenesis and Therapeutic Prospects.International journal of molecular sciences · 2023Review
- Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development.Annals of the rheumatic diseases · 2023Article
- Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation.Biomolecules · 2023Article
- Combination of Two Monoclonal Anti-Citrullinated Protein Antibodies Induced Tenosynovitis, Pain, and Bone Loss in Mice in a Peptidyl Arginine Deiminase-4-Dependent Manner.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.International journal of molecular sciences · 2023Review
- Prevention vs treatment of rheumatoid arthritis.Immunotherapy advances · 2023Review
- Fibromyalgia Pathophysiology.Biomedicines · 2022Review
- Review
- Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain.International journal of molecular sciences · 2022Review
- The autoimmune aetiology of unexplained chronic pain.Autoimmunity reviews · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
24 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractSeveral bone conditions, eg, bone cancer, osteoporosis, and rheumatoid arthritis (RA), are associated with a risk of developing persistent pain. Increased osteoclast activity is often the hallmark of these bony pathologies and not only leads to bone remodeling but is also a source of pronociceptive factors that sensitize the bone-innervating nociceptors. Although historically bone loss in RA has been believed to be a consequence of inflammation, both bone erosion and pain can occur years before the symptom onset. Here, we have addressed the disconnection between inflammation, pain, and bone erosion by using a combination of 2 monoclonal antibodies isolated from B cells of patients with RA. We have found that mice injected with B02/B09 monoclonal antibodies (mAbs) developed a long-lasting mechanical hypersensitivity that was accompanied by bone erosion in the absence of joint edema or synovitis. Intriguingly, we have noted a lack of analgesic effect of naproxen and a moderate elevation of few inflammatory factors in the ankle joints suggesting that B02/B09-induced pain-like behavior does not depend on inflammatory processes. By contrast, we found that inhibiting osteoclast activity and acid-sensing ion channel 3 signaling prevented the development of B02/B09-mediated mechanical hypersensitivity. Moreover, we have identified secretory phospholipase A2 and lysophosphatidylcholine 16:0 as critical components of B02/B09-induced pain-like behavior and shown that treatment with a secretory phospholipase A2 inhibitor reversed B02/B09-induced mechanical hypersensitivity and bone erosion. Taken together, our study suggests a potential link between bone erosion and pain in a state of subclinical inflammation and offers a step forward in understanding the mechanisms of bone pain in diseases such as RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.